Home
About Us
Strategies
Leadership
Portfolio
News
Contact Us
Menu
News
Home
»
News
Timber Pharmaceuticals to be Acquired by LEO Pharma
Mon August 21, 2023 | 09:31 pm
Continue Reading
Visiox Pharma Appoints Richard J. Rubino to Board of Directors
Thu August 17, 2023 | 09:28 pm
Continue Reading
PaxMedica Announces Positive Top Line Results from the PAX-101 (intravenous suramin) Phase 3 African Sleeping Sickness Study, PAX-HAT-301
Mon July 24, 2023 | 09:22 pm
Continue Reading
Visiox Pharma Licenses OMLONTI®
Wed July 19, 2023 | 09:21 pm
Continue Reading
PaxMedica Grants Exclusive Pharmacy Distribution Rights
Thu July 6, 2023 | 09:19 pm
Continue Reading
Timber Pharmaceuticals to Present Interim Analyses from Phase 3 ASCEND Study of TMB-001 in Congenital Ichthyosis
Tue June 20, 2023 | 09:15 pm
Continue Reading
PaxMedica Rings the NASDAQ Closing Bell
Tue April 25, 2023 | 09:08 pm
Continue Reading
PaxMedica Announces NASDAQ Closing Bell Ringing to Celebrate Initial Public Offering and Autism Awareness Month
Wed April 19, 2023 | 08:33 am
Continue Reading
PaxMedica, Inc. Secures $3.2 Million Growth Capital From Lind Partners
Fri February 3, 2023 | 08:00 am
Continue Reading
Visiox Pharma Announces FDA Acceptance of New Drug Application for Glaucoma
Thu December 8, 2022 | 07:58 pm
Continue Reading
PaxMedica, Inc. Enters Into Committed Equity Investment Agreement for up to $20 Million With Lincoln Park Capital
Thu November 17, 2022 | 07:56 pm
Continue Reading
PaxMedica Initiates Clinical Program to Advance PAX-101 Towards FDA Submission
Tue November 8, 2022 | 07:55 pm
Continue Reading
1
2
3
Next »
Search
Menu
Categories
Set your categories menu in Header builder -> Mobile -> Mobile menu element -> Show/Hide -> Choose menu
